United Therapeutics Operating Income 2006-2019 | UTHR

United Therapeutics operating income from 2006 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
United Therapeutics Annual Operating Income
(Millions of US $)
2019 $-188
2018 $805
2017 $815
2016 $1,062
2015 $699
2014 $539
2013 $292
2012 $422
2011 $318
2010 $171
2009 $26
2008 $-82
2007 $6
2006 $29
2005 $43
United Therapeutics Quarterly Operating Income
(Millions of US $)
2019-12-31 $64
2019-09-30 $183
2019-06-30 $221
2019-03-31 $-656
2018-12-31 $132
2018-09-30 $150
2018-06-30 $217
2018-03-31 $307
2017-12-31 $139
2017-09-30 $324
2017-06-30 $89
2017-03-31 $264
2016-12-31 $174
2016-09-30 $239
2016-06-30 $285
2016-03-31 $364
2015-12-31 $155
2015-09-30 $387
2015-06-30 $172
2015-03-31 $-15
2014-12-31 $179
2014-09-30 $-32
2014-06-30 $176
2014-03-31 $216
2013-12-31 $-28
2013-09-30 $105
2013-06-30 $122
2013-03-31 $94
2012-12-31 $129
2012-09-30 $81
2012-06-30 $106
2012-03-31 $107
2011-12-31 $64
2011-09-30 $103
2011-06-30 $114
2011-03-31 $37
2010-12-31 $15
2010-09-30 $62
2010-06-30 $61
2010-03-31 $32
2009-12-31 $-2
2009-09-30 $12
2009-06-30 $-4
2009-03-31 $21
2008-12-31 $-134
2008-09-30 $18
2008-06-30 $19
2008-03-31 $15
2007-12-31 $-8
2007-09-30 $14
2007-06-30 $8
2007-03-31 $-8
2006-12-31 $4
2006-09-30 $11
2006-06-30 $12
2006-03-31 $2
2005-12-31 $10
2005-09-30 $15
2005-06-30 $11
2005-03-31 $7
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.008B $1.449B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $53.083B 30.71
Takeda Pharmaceutical (TAK) Japan $48.710B 8.54
Astellas Pharma (ALPMY) Japan $28.984B 14.48
Eisai (ESALY) Japan $20.745B 38.65
UCB SA (UCBJF) Belgium $16.296B 0.00
Grifols, S.A (GRFS) Spain $14.198B 17.65
Merck (MKGAF) Germany $13.006B 17.06
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Neurocrine Biosciences (NBIX) United States $8.172B 227.03
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.874B 0.00
Catalent (CTLT) United States $7.163B 29.47
Ionis Pharmaceuticals (IONS) United States $6.879B 20.85
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.480B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $5.443B 6.64
Orion OYJ (ORINY) Finland $5.269B 23.61
STADA ARZNEIMI (STDAF) Germany $4.685B 0.00
Forty Seven (FTSV) United States $4.553B 0.00
IPSEN SA ADR (IPSEY) France $4.515B 0.00
Hypermarcas (HYPMY) Brazil $3.914B 11.90
Evotec AG (EVTCY) Germany $3.485B 56.21
Nektar Therapeutics (NKTR) United States $3.059B 0.00
FibroGen (FGEN) United States $2.945B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.859B 53.06
PTC Therapeutics (PTCT) United States $2.527B 0.00
ChemoCentryx (CCXI) United States $2.376B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.271B 9.19
Sage Therapeutics (SAGE) United States $1.635B 0.00
Xencor (XNCR) United States $1.621B 66.19
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.613B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.550B 18.85
Pacira Pharmaceuticals (PCRX) United States $1.334B 36.47
Theravance Biopharma (TBPH) Cayman Islands $1.331B 0.00
Karyopharm Therapeutics (KPTI) United States $1.283B 0.00
USANA Health Sciences (USNA) United States $1.279B 13.43
Corcept Therapeutics (CORT) United States $1.246B 13.94
CLINIGEN GP (CLIGF) United Kingdom $1.103B 0.00
Zogenix (ZGNX) United States $1.060B 0.00
Heron Therapeutics (HRTX) United States $1.021B 0.00
Esperion Therapeutics (ESPR) United States $0.971B 0.00
Tilray (TLRY) Canada $0.947B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.937B 29.03
Akebia Therapeutics (AKBA) United States $0.916B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.898B 12.50
Endo (ENDP) Ireland $0.787B 1.45
Translate Bio (TBIO) United States $0.649B 0.00
ImmunoGen (IMGN) United States $0.645B 0.00
Molecular Templates (MTEM) United States $0.645B 0.00
Radius Health (RDUS) United States $0.608B 0.00
Aerie Pharmaceuticals (AERI) United States $0.606B 0.00
Collegium Pharmaceutical (COLL) United States $0.561B 0.00
Portola Pharmaceuticals (PTLA) United States $0.536B 0.00
Indivior (INVVY) United States $0.480B 2.85
Catalyst Pharmaceuticals (CPRX) United States $0.390B 13.00
Innate Pharma SA (IPHYF) France $0.385B 0.00
Siga Technologies (SIGA) United States $0.384B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.378B 15.51
Corbus Pharmaceuticals Holdings (CRBP) United States $0.377B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.374B 0.00
Ardelyx (ARDX) United States $0.368B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.356B 0.00
Organogenesis Holdings (ORGO) United States $0.354B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.339B 0.00
Trillium Therapeutics (TRIL) Canada $0.328B 0.00
Flexion Therapeutics (FLXN) United States $0.317B 0.00
Calithera Biosciences (CALA) United States $0.311B 0.00
DURECT (DRRX) United States $0.305B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.295B 0.00
TherapeuticsMD (TXMD) United States $0.293B 0.00
Lannett Co Inc (LCI) United States $0.292B 4.71
Harpoon Therapeutics (HARP) United States $0.286B 0.00
Concert Pharmaceuticals (CNCE) United States $0.277B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.265B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.263B 0.00
Ocular Therapeutix (OCUL) United States $0.259B 0.00
CASI Pharmaceuticals (CASI) United States $0.206B 0.00
OptiNose (OPTN) United States $0.184B 0.00
Rafael Holdings (RFL) United States $0.183B 0.00
Jounce Therapeutics (JNCE) United States $0.161B 2.90
Recro Pharma (REPH) United States $0.155B 0.00
Nature's Sunshine Products (NATR) United States $0.152B 19.10
PROFOUND MEDICL (PROF) Canada $0.146B 0.00
MEI Pharma (MEIP) United States $0.142B 0.00
Taiwan Liposome (TLC) Taiwan $0.139B 0.00
KalVista Pharmaceuticals (KALV) United States $0.130B 0.00
VAXART, INC (VXRT) United States $0.123B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.119B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.102B 0.00
CannTrust Holdings (CTST) Canada $0.099B 0.00
Redhill Biopharma (RDHL) Israel $0.092B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.086B 0.00
IMV INC (IMV) Canada $0.084B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.081B 0.00
Champions Oncology (CSBR) United States $0.079B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.078B 0.00
Xeris Pharmaceuticals (XERS) United States $0.077B 0.00
Aquestive Therapeutics (AQST) United States $0.077B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.073B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.073B 0.00
SCYNEXIS (SCYX) United States $0.071B 0.00
CTI BioPharma (CTIC) United States $0.069B 0.00
CV Sciences (CVSI) United States $0.069B 0.00
Biomerica (BMRA) United States $0.069B 0.00
Otonomy (OTIC) United States $0.063B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.053B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.052B 16.43
Infinity Pharmaceuticals (INFI) United States $0.051B 0.00
Aclaris Therapeutics (ACRS) United States $0.047B 0.00
Nivalis Therapeutics (ALPN) United States $0.046B 0.00
PolarityTE (PTE) United States $0.045B 0.00
MediWound (MDWD) Israel $0.045B 0.00
Onconova Therapeutics (ONTX) United States $0.044B 0.00
PharmAthene (ALT) United States $0.044B 0.00
GTx (ONCT) United States $0.043B 0.00
Natural Alternatives (NAII) United States $0.043B 19.41
Neos Therapeutics (NEOS) United States $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.039B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.039B 131.14
Forward Pharma (FWP) Denmark $0.038B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.037B 0.00
Heat Biologics (HTBX) United States $0.034B 0.00
Jaguar Animal Health (JAGX) United States $0.027B 0.00
Mannatechorporated (MTEX) United States $0.026B 8.05
Bellicum Pharmaceuticals (BLCM) United States $0.024B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.023B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.023B 0.00
Novan (NOVN) United States $0.021B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.021B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Lipocine (LPCN) United States $0.020B 0.00
Cardiome Pharma (CORV) Canada $0.020B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
China SXT Pharmaceuticals (SXTC) China $0.018B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Vical (BBI) United States $0.013B 0.00
ElectroCore (ECOR) United States $0.012B 0.00
Cyanotech (CYAN) United States $0.012B 0.00
Shineco (TYHT) China $0.012B 0.00
KemPharm (KMPH) United States $0.012B 0.00
Regulus Therapeutics (RGLS) United States $0.010B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.008B 0.00
Midatech Pharma (MTP) United Kingdom $0.008B 0.00
HANCOCK JAFFE (HJLI) United States $0.006B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.005B 0.00
Flex Pharma (SLRX) United States $0.003B 0.00
Xenetic Biosciences (XBIO) United States $0.003B 0.00
RXi Pharmaceuticals (PHIO) United States $0.001B 0.00